First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306). (nature.com)

Authors: Yoon HH … Xu J Journal: Nature Communications Published: 2026-09-03 DOI: https://doi.org/10.1038/s41467-026-77327-0